The The Audit Of Using Of Statins Following A Diagnosis Of Acute Coronary Syndrome (ACS) In The Royal Alexandra Hospital

Abstract

Background

Statins are well-founded for the acute coronary syndrome as a secondary prevention therapy. Recent GGC guidelines recommend the use of maximum atorvastatin dose (80 mg).

Methodology  

An audit was performed on all patients who had a clear diagnosis of ACS during admission at RAH within three weeks period(August 2019). Data collected from patient's medications chart, electronic system and medical note. IT included age, gender,  statin before admission, statin during admission, lipid profiles, contraindication to statin use.

Results

72 patients were diagnosed with ACS through the audit period at an average age of 64 years. 61% (n=44) were men and 39% (n=28) were women. 60% (n=43) of the patients before admission on a statin. although of known ACS, 8% (n=6) of all patients had no lipid-lowering treatment. During admission, 33 per cent (n=24) of patients with ACS were measured the lipid profile. 61% (n=44) of cases received maximum atorvastatin dose. Only 22 % of those not licensed for the GGC guideline dose had clear side effects. 

Conclusion

The current audit showed that 39 per cent of patients diagnosed with ACS did not receive a maximum dose of atorvastatin during admission, with only a 22 per cent of patients having side effects from using a statin. The results indicate non-compliance with GGC guidelines regarding the use of appropriate statin following a diagnosis of ACS during admission. future Plans will include applying new GGC guidance and medical team training sessions to emphasize evidence-based practices.